V.A. Miller - Concepedia

Author

V.A. Miller

Memorial Sloan Kettering Cancer Center

Also Known As

H Ou, Miller, V.A., Miller, Veronica, V A Miller, V MILLER, V Miller, V. A. Miller, V. Miller, V.A Miller, V.A. Miller

133

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Foundation Medicine (United States)Albany Medical Center Hospital Cornell University Dana-Farber Cancer Institute

About

V.A. Miller is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	26	2.4K
2	Health Sciences	5	5	428
3	Engineering	1	1	99
4	Public Health	1	1	72
5	Biochemistry	1	1	30

V.A. Miller

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Francis M. Sirotnak, Maureen F. Zakowski, V.A. Miller, PubMed ImmunologyPharmacotherapyHuman Tumor XenograftsTumor BiologyCancer Cell Biology	2000	761
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer Alexa B. Schrock, Ching Ouyang, Jaideep Sandhu, Annals of Oncology	2019	616
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer Aria Vaishnavi, Marzia Capelletti, Anh T. Le, Nature Medicine Oncogenic AgentPathologyCancer GeneticsMedicineLung Cancer	2013	582
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer Christian Grommes, Geoffrey R. Oxnard, Mark G. Kris, Neuro-Oncology	2011	341
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing Christine H. Chung, Violeta Beleva Guthrie, David L. Masica, Annals of Oncology	2015	202
A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) V.A. Miller, Arabinda K. Das, M. Rossi Journal of Clinical Oncology Cancer ManagementPathologyFirst-line TreatmentPharmacotherapyMay 30	2009	193
TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) Roy S. Herbst, Diane Prager, Róbert Hermann, Journal of Clinical Oncology	2004	131
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution Ilya Glezerman, Mark G. Kris, V.A. Miller, Clinical Nephrology	2009	112
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B. Schrock, Annals of Oncology	2018	112
Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Fairooz F. Kabbinavar, V.A. Miller, B. E. Johnson, Journal of Clinical Oncology Cancer ManagementPathologyFirst-line TreatmentOverall SurvivalOncology	2010	110

Page 1